CHRONIC CYCLOSPORINE A THERAPY IN RATS

被引:17
|
作者
MIDHA, R [1 ]
MACKINNON, SE [1 ]
WADE, JA [1 ]
EVANS, PJ [1 ]
BEST, TJ [1 ]
WONG, PY [1 ]
机构
[1] WASHINGTON UNIV,SCH MED,SUITE 17424 E PAVIL,1 BARNES HOSP PL,ST LOUIS,MO 63110
关键词
D O I
10.1002/micr.1920130516
中图分类号
R61 [外科手术学];
学科分类号
摘要
We investigated the pharmacokinetics of cyclosporin A (CsA) blood levels and drug toxicity in a chronic rat study in which long-term (30 weeks) CsA was administered. Ninety Lewis rats received subcutaneous CsA at 5 mg/kg/day for 12 weeks, at which time CsA injections were stopped in 50 animals. The remaining 40 rats were maintained on 5 mg/kg CsA daily until week 18 and then switched to an alternate day dosing until week 30. All rats were observed daily and weighed weekly. Whole blood CsA levels were determined by a commercially available radioimmunoassay kit. The daily dosing regimen resulted in greatly elevated trough CsA levels (> 1,600-mu-g/liter) and substantial chronic systemic toxicity, with weight loss and death in eight animals. Alternate day dosing reduced trough levels (mean 1,311-mu-g/liter) and decreased toxicity. Chronic administration by the subcutaneous route resulted in a considerable depot effect, with constancy of drug levels over a 48 hr dosing interval and a slow decline of drug levels (15 days) upon cessation of treatment. These results underscore the importance of monitoring both body weight and blood CsA levels in rodent studies when CsA is employed. Investigators should be aware of drug accumulation with chronic therapy and the consequent need to modify dosing to prevent toxicity.
引用
收藏
页码:273 / 276
页数:4
相关论文
共 50 条
  • [31] Arteriolopathy is reversible after drug withdrawal in rats with chronic cyclosporine nephrotoxicity.
    Andoh, TF
    Franceschini, N
    Alpers, CE
    Bennett, WM
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A2403 - A2403
  • [32] Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension
    Takeda, Y
    Inaba, S
    Furukawa, K
    Fujimura, A
    Miyamori, I
    Mabuchi, H
    JOURNAL OF HYPERTENSION, 2000, 18 (07) : 927 - 933
  • [33] VASOMOTOR RESPONSES IN CYCLOSPORINE A-TREATED RATS AFTER CHRONIC ANGIOTENSIN BLOCKADE
    AUCHSCHWELK, W
    DUSKE, E
    HINK, U
    BETZ, M
    UNKELBACH, M
    HYPERTENSION, 1994, 23 (06) : 832 - 837
  • [34] CYCLOSPORINE AND CHRONIC SARCOIDOSIS
    YORK, EL
    KOVITHAVONGS, T
    MAN, SFP
    REBUCK, AS
    SPROULE, BJ
    CHEST, 1990, 98 (04) : 1026 - 1029
  • [35] Structural skeletal impairment induced by immunosuppressive therapy in rats:: cyclosporine A vs tacrolimus
    Abdelhadi, M
    Ericzon, BG
    Hultenby, K
    Sjöden, G
    Reinholt, FP
    Nordenström, J
    TRANSPLANT INTERNATIONAL, 2002, 15 (04) : 180 - 187
  • [36] Chronic cyclosporine nephrotoxicity
    Andoh, TF
    Bennett, WM
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1998, 7 (03): : 265 - 270
  • [37] Cyclosporine A therapy of chronic lymphoblastic leukemia-related pancytopenia: A case report
    Wang, Mengying
    Meng, Ruoyu
    Gao, Yan
    Huang, Junxia
    Li, Tianlan
    Mao, Chunxia
    Liu, Shanshan
    Xu, Yujie
    Xu, Han
    Feng, Xianqi
    CLINICAL CASE REPORTS, 2022, 10 (03):
  • [38] OVERVIEW OF CYCLOSPORINE-A (CSPA) THERAPY IN CHRONIC INFLAMMATORY BOWEL DISEASES (IBD)
    GOEL, S
    SILVER, D
    SAMADAR, A
    MURTHY, SN
    GASTROENTEROLOGY, 1995, 108 (04) : A824 - A824
  • [39] Infliximab salvage therapy after cyclosporine in an acute flare of chronic ulcerative colitis
    Lam, ECS
    Bailey, RJ
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 17 (03): : 198 - 200
  • [40] Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticaria
    Endo, Takahiro
    Toyoshima, Shota
    Kanegae, Kazuko
    Izaki, Satoshi
    Nishimori, Nobuyuki
    Ito, Mana
    Sugai, Kazuko
    Hayama, Koremasa
    Terui, Tadashi
    Okayama, Yoshimichi
    ALLERGOLOGY INTERNATIONAL, 2019, 68 (02) : 270 - 273